{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T12:09:09Z","timestamp":1787400549185,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":1785,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/gim.2016.117","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T11:23:58Z","timestamp":1473333838000},"page":"275-282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature"],"prefix":"10.1016","volume":"19","author":[{"given":"Antonio","family":"Pisani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Bruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Sabbatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Imbriaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/gim.2016.117_bb0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"2741","article-title":"Fabry disease: alpha galactosidase A deficiency","author":"Desnick","year":"1995"},{"key":"10.1038\/gim.2016.117_bb0015","author":"Faggiano"},{"key":"10.1038\/gim.2016.117_bb0020","author":"Desnick"},{"key":"10.1038\/gim.2016.117_bb0025","first-page":"1","article-title":"Antiproteinuric effect of add-on Paricalcitol in Fabry disease patients: a prospective observational study","volume":"0","author":"Pisani","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/gim.2016.117_bb0030","author":"Pisani"},{"key":"10.1038\/gim.2016.117_bb0035","author":"Pisani"},{"key":"10.1038\/gim.2016.117_bb0040","author":"Lidove"},{"key":"10.1038\/gim.2016.117_bb0045","unstructured":"Europeans Medicines Agency. Assessment report on the shortage of Fabrazyme. Overview of shortage period: Spontaneous reports from June 2009 through 15 September 2010 and Registry data from June 2009 through 05 August 2010. 19 November 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2010\/11\/WC500099241.pdf."},{"key":"10.1038\/gim.2016.117_bb0050","unstructured":"European Medicines Agency. European Medicines Agency reviews treatment recommendations for Fabrazyme. 22 October 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2010\/10\/WC500098370.pdf."},{"key":"10.1038\/gim.2016.117_bb0055","author":"European Medicines Agency"},{"key":"10.1038\/gim.2016.117_bb0060","author":"Stroup"},{"key":"10.1038\/gim.2016.117_bb0065","author":"Tan"},{"key":"10.1038\/gim.2016.117_bb0070","author":"Melzack"},{"key":"10.1038\/gim.2016.117_bb0075","author":"Whybra"},{"key":"10.1038\/gim.2016.117_bb0080","series-title":"SF-36 Health Survey: Manual and Interpretation Guide","author":"Ware","year":"1997"},{"key":"10.1038\/gim.2016.117_bb0085","author":"The EuroQoL Group."},{"key":"10.1038\/gim.2016.117_bb0090","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","author":"Higgins","year":"2011"},{"key":"10.1038\/gim.2016.117_bb0095","author":"Bagos"},{"key":"10.1038\/gim.2016.117_bb0100","author":"Lin"},{"key":"10.1038\/gim.2016.117_bb0105","author":"Smid"},{"key":"10.1038\/gim.2016.117_bb0110","author":"Tsuboi"},{"key":"10.1038\/gim.2016.117_bb0115","author":"Lenders"},{"key":"10.1038\/gim.2016.117_bb0120","author":"Pisani"},{"key":"10.1038\/gim.2016.117_bb0125","unstructured":"Wakabayashi T, Sakuma M, Morita A, et al. The effect of switching treatment from agalsidase-\u03b2 to agalsidase-\u03b1 on renal function in 18 adults with Fabry disease. 12th International Congress of Inborn Errors of Metabolism (ICIEM), Barcelona, 3\u20136 September 2013."},{"key":"10.1038\/gim.2016.117_bb0130","author":"Goker-Alpan"},{"key":"10.1038\/gim.2016.117_bb0135","unstructured":"West M, Bichet DG, Casey R, et al. The Canadian Fabry Initiative. Lysosomal Storage Disease Network WORLD Symposium, San Diego, CA, 8\u201310 February 2012."},{"key":"10.1038\/gim.2016.117_bb0140","author":"Reidt"},{"key":"10.1038\/gim.2016.117_bb0145","author":"Weidemann"},{"key":"10.1038\/gim.2016.117_bb0150","author":"Sirrs"},{"key":"10.1038\/gim.2016.117_bb0155","first-page":"S153","article-title":"Experience of switching enzyme replacement therapy (ERT) products in patients with Anderson Fabry disease: a specialist nurse perspective","volume":"33(suppl 1)","author":"Thompson","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/gim.2016.117_bb0160","author":"CFDI investigators"},{"key":"10.1038\/gim.2016.117_bb0165","first-page":"S1","article-title":"Our experiences of switching patients from Fabrazyme to Replagal at Salford Royal NHS Foundation Trust","volume":"33(suppl 1)","author":"Hallows","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/gim.2016.117_bb0170","author":"Tanaka"},{"key":"10.1038\/gim.2016.117_bb0175","first-page":"S228","article-title":"Switch from Fabrazyme to Replagal in the treatment of patients with Fabry disease: the need for an individual approach","volume":"34(suppl 3)","author":"Eyskens","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/gim.2016.117_bb0180","author":"Tsuboi"},{"key":"10.1038\/gim.2016.117_bb0185","author":"Warnock"},{"key":"10.1038\/gim.2016.117_bb0190","author":"Pisani"},{"key":"10.1038\/gim.2016.117_bb0195","author":"Tsuboi"},{"key":"10.1038\/gim.2016.117_bb0200","unstructured":"Pisani A, Visciano B, Capuano I, et al. A comparison of the therapeutic efficacy of two different enzyme treatments in Fabry\u2019s disease: from evidence in the literature to personal experience. G Ital Nefol 2013;30."},{"key":"10.1038\/gim.2016.117_bb0205","unstructured":"Riccio E, Pisani A. [The switch of enzyme therapy in Fabry disease]. G Ital Nefrol 2014;31."}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/gim2016117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gim2016117","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360021024175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360021024175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gim2016117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:46:31Z","timestamp":1761097591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360021024175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1098360021024175"],"URL":"https:\/\/doi.org\/10.1038\/gim.2016.117","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/gim.2016.117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017, The Author(s), under exclusive licence to the American College of Medical Genetics and Genomics","name":"copyright","label":"Copyright"}]}}